Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Nkarta, Inc. logo — A New Way Forward for Autoimmune Disease

Nkarta, Inc.

A New Way Forward for Autoimmune Disease

Founded 2015 United States South San Francisco, United States 157 employees Post-IPO Equity Total: $595.00M Biotechnology, Health Care

General Information

Company Name Nkarta, Inc.
Founded Year 2015
Location United States South San Francisco, United States
Employees 157
Industries Biotechnology, Health Care
Funding Stage Post-IPO Equity
Business Model B2B, B2D
Revenue Model Licensing, Performance Based, Project Based
Social

BounceWatch is an independent company data service, not affiliated with Nkarta, Inc.. To contact Nkarta, Inc., visit nkartatx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Nkarta, Inc. compare?

A PDF of Nkarta, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Nkarta, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Nkarta, Inc.

Nkarta, Inc., founded in 2015, is at the forefront of innovative biotechnology solutions aimed at tackling autoimmune diseases. Their slogan, "A New Way Forward for Autoimmune Disease", reflects their pioneering approach in the Biotechnology and Health Care sectors.

The company specializes in developing allogeneic natural killer (NK) cell therapies. Utilizing a unique combination of cell expansion, cryopreservation platforms, and proprietary cell engineering technologies, Nkarta is advancing a promising pipeline of cell therapy candidates. These candidates benefit from efficient manufacturing processes and are specially designed to enhance tumor targeting and improve persistence within the body.

Headquartered in the United States, Nkarta secured a substantial $240.00M post-IPO equity investment on 25 March 2024, backed by a strong coalition of investors including RA Capital Management, OrbiMed, Adage Capital Management, Commodore Capital, EcoR1 Capital, Janus Henderson, Ridgeback Capital, Samsara BioCapital, SR One, and Cormorant Asset Management. This investment underscores the investor confidence in Nkarta's groundbreaking work and growth potential in the field of biotechnological therapeutics.

Business keywords: Allogeneic NK Cells, Cell Therapy, Immuno-Oncology, Tumor Targeting, Cell Engineering, Cryopreservation, Cell Expansion, Hematologic Malignancies, Solid Tumor Malignancies, Therapy Manufacturing, Cancer Research, Natural Killer Cells, Oncology Therapeutics, Autoimmune Disease Treatment

Services & Products

Development of immunotherapy drugs
Conducting clinical trials
Research and development of NK cell technology

Target Customers

Patients with autoimmune diseases Healthcare providers Medical researchers

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $240.00M 10
RA Capital Management OrbiMed Adage Capital Management
RA Capital Management, OrbiMed +8
25 Mar 2024
Post IPO Equity $230.00M -
25 Apr 2022
Series B $114.00M -
04 Sep 2019
Series A $11.00M -
01 Jan 2015

Nkarta, Inc. Alternatives & Competitors

View All Alternatives
Nkarta, Inc. vs
Adicet Bio, Inc
Adicet Bio, Inc United States

A biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR t cell...

IPO
124 employees
Biopharma, Biotechnology
Nkarta, Inc. vs
Fate Therapeutics Inc.
Fate Therapeutics Inc. United States

Transforming the lives of patients with autoimmune diseases and cancer.

227 employees
Biotechnology, Health Care
Nkarta, Inc. vs
Kite Pharma
Kite Pharma United States

At Kite, a Gilead Company, our singular focus is cell therapy to treat and cure cancer.

Acquired
4013 employees
Biotechnology, Health Care
Also compare with: Nkarta, Inc. vs Caribou Biosciences Caribou Biosciences Nkarta, Inc. vs TScan Therapeutics TScan Therapeutics View all alternatives

FAQ About Nkarta, Inc.

A New Way Forward for Autoimmune Disease
Nkarta, Inc. was founded in 2015.
Nkarta, Inc. is headquartered in South San Francisco, United States.
Nkarta, Inc. operates in Biotechnology and Health Care. Its work centres on Allogeneic NK Cells, Cell Therapy, Immuno-Oncology and Tumor Targeting. Its customers include Patients with autoimmune diseases, Healthcare providers and Medical researchers.
Nkarta, Inc. has a B2B and B2D business model. Its revenue comes from Licensing, Performance Based and Project Based.
Nkarta, Inc. has approximately 157 employees.
Nkarta, Inc. has completed 4 funding rounds, raising a total of $595.00M. The latest funding stage is Post-IPO Equity.
Nkarta, Inc. offers: Development of immunotherapy drugs, Conducting clinical trials, Research and development of NK cell technology.
Top alternatives and competitors to Nkarta, Inc. include Adicet Bio, Inc, Fate Therapeutics Inc., Kite Pharma, Gracell Biotechnologies, Caribou Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Nkarta, Inc. and Adicet Bio, Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Nkarta, Inc., https://bouncewatch.com/company/nkarta-inc, updated 4 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes